FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 468 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... August 8, 2018 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 Load more HOT NEWS Bean there done that: Can swapping to pulses be the new... Coronavirus reports – Part 6 “The kids being home all the... Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial...
